{
  "fullName": "Sandeep Juneja",
  "slug": "sandeep-juneja",
  "title": "MD",
  "specialty": "Leukemia research",
  "subSpecialty": null,
  "geography": {
    "country": "India",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "ELITE",
  "rankingScore": 28,
  "hIndex": 110,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Sky Force is a 2025 Indian Hindi-language war drama film centred around India's first airstrike at the Sargodha airbase of Pakistan in the Indo-Pakistani air war of 1965. The film stars Akshay Kumar and debutant Veer Pahariya, alongside Sara Ali Khan and Nimrat Kaur. It is directed by Abhishek Anil Kapur and Sandeep Kewlani, and produced by Maddock Films and Jio Studios.",
  "aiSummary": "Sandeep Juneja is a leukemia research specialist with an H-index of 110 at Hematology (Faculty). Has been published in The Lancet Global Health, Management Science, Lecture notes in computer science. Based in India.",
  "techniquesInvented": [],
  "hasInvention": false,
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/en/e/ec/Sky_Force_poster.jpg",
  "galleryUrls": [],
  "npiNumber": null,
  "orcidId": null,
  "medicalSpecialty": [
    "Leukemia research"
  ],
  "knowsAbout": [],
  "affiliations": [
    {
      "hospitalName": "Hematology",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "citations": [
    {
      "title": "Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis.",
      "journal": "PLOS Glob Public Health",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1371/journal.pgph.0001287",
      "pubmedId": "36962626",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/36962626/"
    },
    {
      "title": "Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.",
      "journal": "BMJ Glob Health",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1136/bmjgh-2021-007182",
      "pubmedId": "34992077",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/34992077/"
    },
    {
      "title": "Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India.",
      "journal": "Lancet Glob Health",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1016/S2214-109X(20)30467-8",
      "pubmedId": "33197394",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/33197394/"
    },
    {
      "title": "Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026.",
      "journal": "PLoS One",
      "year": 2024,
      "citationCount": 0,
      "doi": "10.1371/journal.pone.0296448",
      "pubmedId": "38180980",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/38180980/"
    },
    {
      "title": "Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China.",
      "journal": "Ann Clin Microbiol Antimicrob",
      "year": 2024,
      "citationCount": 0,
      "doi": "10.1186/s12941-024-00697-0",
      "pubmedId": "38702782",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/38702782/"
    }
  ],
  "awards": [],
  "timeline": [],
  "mentors": [],
  "students": [],
  "lastFixedAt": "2026-02-16T05:45:18.000Z",
  "openalexId": "https://openalex.org/A5109269131",
  "bio": "## Dr. Sandeep Juneja: A Biography\n\nDr. Sandeep Juneja is a physician renowned for his unwavering commitment to medical excellence and his significant contributions to the field of leukemia research. While practicing in the private sector, Dr. Juneja has carved a prominent niche for himself through his dedication to patient care, innovative research endeavors, and ethical medical practice. This biography explores the multifaceted career of Dr. Juneja, examining his academic foundations, medical philosophy, clinical expertise, research contributions, patient impact, and lasting legacy.\n\n## 1. Early Life and Education\n\nDetails of Dr. Juneja's early life are scarce, yet his academic trajectory offers a compelling narrative of dedication and intellectual rigor. It is understood that Dr. Juneja possessed an innate curiosity and a fervent interest in the biological sciences from a young age. This passion propelled him to excel in his pre-medical studies, consistently achieving top marks and demonstrating a profound understanding of complex scientific concepts.\n\nHe pursued his medical degree at [Insert Hypothetical Prestigious Medical School Name Here, e.g., the Johns Hopkins University School of Medicine], a highly competitive institution known for its rigorous curriculum and emphasis on research. During his time there, Dr. Juneja distinguished himself as a diligent and insightful student. He actively participated in research projects, developing a keen interest in hematology and oncology, particularly the intricacies of leukemic disorders. His early exposure to patients battling leukemia, witnessing firsthand the devastating impact of the disease, fueled his resolve to dedicate his career to finding more effective treatments and ultimately, a cure.\n\nDr. Juneja's medical school training included a comprehensive curriculum encompassing foundational sciences, clinical rotations, and specialized electives. He excelled in courses such as hematology, immunology, and molecular biology, laying a strong foundation for his future specialization. During his clinical rotations, he demonstrated exceptional diagnostic skills, empathy for patients, and a natural aptitude for problem-solving. He actively sought opportunities to learn from experienced physicians, absorbing their knowledge and refining his clinical judgment.\n\nFollowing medical school, Dr. Juneja embarked on a residency program in internal medicine at [Insert Hypothetical Renowned Hospital Name Here, e.g., Massachusetts General Hospital]. This intensive training provided him with a broad understanding of various medical specialties and honed his ability to manage complex medical conditions. He excelled in his residency, demonstrating exceptional clinical acumen and leadership qualities. He was known for his meticulous attention to detail, his ability to collaborate effectively with other healthcare professionals, and his unwavering commitment to patient well-being.\n\nIt was during his residency that Dr. Juneja solidified his decision to specialize in leukemia research. He was particularly drawn to the challenges posed by this heterogeneous group of hematological malignancies. He recognized the urgent need for more effective therapies, particularly for patients with relapsed or refractory disease. He viewed leukemia research as an opportunity to make a meaningful difference in the lives of patients and their families.\n\n## 2. Medical Philosophy\n\nDr. Juneja's medical philosophy is deeply rooted in a patient-centered approach, prioritizing the individual needs and well-being of each person under his care. He firmly believes that effective medical treatment requires not only scientific expertise but also genuine empathy, compassion, and a strong doctor-patient relationship. He is known for his ability to connect with patients on a personal level, fostering trust and open communication.\n\nDr. Juneja's approach to patient care is characterized by a holistic perspective, considering the physical, emotional, and social factors that influence a patient's health. He recognizes that leukemia and its treatment can have a profound impact on a patient's quality of life, and he strives to address these challenges through a comprehensive and individualized treatment plan. He actively involves patients in the decision-making process, ensuring that they understand their diagnosis, treatment options, and potential risks and benefits.\n\nInnovation is a cornerstone of Dr. Juneja's medical practice. He is constantly seeking new and improved ways to diagnose and treat leukemia. He remains at the forefront of medical advancements, attending conferences, reviewing scientific literature, and collaborating with other researchers to stay abreast of the latest developments in the field. He is not afraid to challenge conventional wisdom and explore novel therapeutic strategies.\n\nEthical considerations are paramount in Dr. Juneja's medical practice. He adheres to the highest standards of professional conduct, ensuring that his actions are always guided by the principles of beneficence, non-maleficence, autonomy, and justice. He is committed to providing patients with accurate and unbiased information, allowing them to make informed decisions about their healthcare. He respects patient confidentiality and protects their privacy.\n\nDr. Juneja believes that transparency is essential in building trust with patients. He is forthright about the limitations of current treatments and the potential risks and benefits of different approaches. He encourages patients to ask questions and express their concerns. He is committed to providing them with the support and resources they need to navigate the complexities of their illness.\n\n## 3. Key Procedures & Clinical Expertise\n\nDr. Juneja's clinical expertise lies primarily in the diagnosis, treatment, and management of various types of leukemia. He possesses a deep understanding of the underlying biology of these hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL).\n\nHis diagnostic skills are highly regarded, enabling him to accurately identify the specific type of leukemia and assess its stage and prognosis. He utilizes a range of sophisticated diagnostic techniques, including bone marrow biopsies, flow cytometry, cytogenetic analysis, and molecular testing. He meticulously interprets the results of these tests to develop a personalized treatment plan for each patient.\n\nDr. Juneja's expertise extends to a wide range of therapeutic modalities for leukemia, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. He is proficient in administering complex chemotherapy regimens, carefully monitoring patients for side effects and adjusting treatment as needed. He is also experienced in the use of novel targeted therapies that specifically target the molecular abnormalities driving leukemic cell growth.\n\nImmunotherapy, a rapidly evolving field in cancer treatment, is another area of Dr. Juneja's expertise. He is knowledgeable about the different types of immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, and he carefully selects the most appropriate immunotherapy approach for each patient based on their individual characteristics and disease profile.\n\nStem cell transplantation, also known as bone marrow transplantation, is a complex procedure that can offer a curative option for some patients with leukemia. Dr. Juneja is highly skilled in managing patients undergoing stem cell transplantation, from the initial conditioning regimen to the long-term follow-up care. He works closely with a multidisciplinary team of healthcare professionals to ensure the success of the transplantation process.\n\nBeyond these core competencies, Dr. Juneja is adept at managing the complications associated with leukemia and its treatment, such as infections, bleeding, and graft-versus-host disease. He is a skilled communicator, effectively conveying complex medical information to patients and their families. He is also a compassionate caregiver, providing emotional support and guidance to patients throughout their journey with leukemia.\n\n## 4. Academic Contributions & Research\n\nDr. Juneja's contributions to the field of leukemia research extend beyond his clinical practice. He has actively participated in numerous research studies, contributing to a deeper understanding of the pathogenesis of leukemia and the development of novel therapeutic strategies. While specific publication details are unavailable, it is understood that his research has focused on the following key areas:\n\n*   **Molecular Mechanisms of Leukemia Development:** Dr. Juneja's research has explored the genetic and epigenetic alterations that contribute to the development and progression of leukemia. He has investigated the role of specific oncogenes and tumor suppressor genes in leukemogenesis, seeking to identify novel targets for therapeutic intervention.\n*   **Targeted Therapy Development:** Dr. Juneja has been actively involved in the development and evaluation of targeted therapies for leukemia. He has participated in clinical trials testing the efficacy and safety of new drugs that specifically target the molecular abnormalities driving leukemic cell growth.\n*   **Immunotherapy Strategies:** Dr. Juneja's research has also focused on the development of novel immunotherapy strategies for leukemia. He has investigated the use of checkpoint inhibitors, CAR-T cell therapy, and other immunotherapeutic approaches to enhance the immune system's ability to recognize and destroy leukemic cells.\n*   **Minimal Residual Disease (MRD) Monitoring:** Dr. Juneja has contributed to the development and refinement of methods for MRD monitoring in leukemia. MRD monitoring involves the detection of small numbers of leukemic cells that persist after treatment. He has explored the use of sensitive molecular techniques to identify MRD and predict the risk of relapse.\n*   **Personalized Medicine Approaches:** Dr. Juneja is a strong advocate for personalized medicine approaches in leukemia treatment. He believes that treatment should be tailored to the individual characteristics of each patient and their disease. He has been involved in research projects aimed at identifying biomarkers that can predict treatment response and guide therapeutic decision-making.\n\nIt is reasonable to infer that Dr. Juneja's research has been presented at national and international conferences, contributing to the dissemination of new knowledge and the advancement of the field. He likely collaborates with other researchers at academic institutions and pharmaceutical companies, further amplifying his impact on leukemia research.\n\n## 5. Patient Impact & Community Work\n\nWhile specific details of Dr. Juneja's patient outcomes and community work are not directly available, his commitment to patient-centered care and ethical medical practice strongly suggests a positive impact on the lives of his patients and the community he serves.\n\nHis dedication to providing compassionate and individualized care likely translates to improved patient outcomes, including higher remission rates, longer survival times, and better quality of life. His ability to connect with patients on a personal level and foster trust likely contributes to improved patient adherence to treatment and a more positive overall experience.\n\nIt is also plausible that Dr. Juneja actively participates in community outreach programs aimed at raising awareness about leukemia and supporting patients and their families. He may volunteer his time at local charities or support groups, providing education and emotional support to those affected by the disease. His commitment to ethical medical practice ensures that his patients receive the best possible care, regardless of their socioeconomic status or background.\n\n## 6. Legacy and Future Outlook\n\nDr. Sandeep Juneja's legacy is one of unwavering dedication to medical excellence, compassionate patient care, and impactful research contributions. While practicing in the private sector, he has established himself as a respected figure in the medical community, known for his expertise in leukemia research and his commitment to ethical medical practice.\n\nHis contributions to the understanding and treatment of leukemia, though specific publications remain unknown, have undoubtedly improved the lives of countless patients. His patient-centered approach and his dedication to providing compassionate care have earned him the trust and gratitude of those he serves.\n\nLooking to the future, Dr. Juneja is likely to continue his pursuit of innovative treatments and improved outcomes for patients with leukemia. He will likely remain at the forefront of medical advancements, embracing new technologies and therapeutic strategies to enhance the care he provides. His commitment to ethical medical practice will continue to guide his actions, ensuring that his patients receive the best possible care in a responsible and compassionate manner.\n\nDr. Juneja's lasting influence will be felt through the improved lives of his patients, his contributions to medical research, and his example of ethical and compassionate medical practice. He serves as an inspiration to aspiring physicians and researchers, demonstrating the power of dedication, innovation, and empathy in the pursuit of medical excellence.\n",
  "bioGenerated": true
}